PRESS RELEASE: Flemming Lindeløv is leaving the Lundbeck Supervisory Board

Flemming Lindeløv is leaving the Lundbeck Supervisory Board

Flemming Lindeløv has today informed the Supervisory Board of H. Lundbeck A/S that he has decided to resign his duties as Chairman and withdraw from the Lundbeck Supervisory Board as of today in order to restore some calm around the company.
The Supervisory Board of H. Lundbeck A/S has consequently at an extraordinary Board meeting decided to constitute itself with Per Wold-Olsen as new Chairman of the Board. Subsequently, Per Wold-Olsen will take up the position of Chairman at this time and not in connection with the Annual General Meeting as previously announced.

The Supervisory Board and Lundbeck Management will henceforth now focus their work on Lundbeck's business and the strategic challenges that the company is facing.

The content of this release will have no influence on the Lundbeck Group's financial result for 2007.

About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2006, the company's revenue was DKK 9.2 billion (approximately EUR 1.2 billion or USD 1.6 billion). The number of employees is approximately 5,300 globally. For further information, please visit

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.